Akebia Therapeutics

AKBA65

Penny Stock

$1.37arrow_drop_up1.48%$0.02

Penny Stock

AKBA65

$1.37

arrow_drop_up1.48%$0.02

Penny Stock

Performance History

Key Stats
Open	$1.39
Prev. Close	$1.35
EPS	-0.21
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$283.88M
PE Ratio	-

	LOW	HIGH
Day Range	1.34	1.39
52 Week Range	0.78	2.48

Ratios







EPS	-0.21

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Akebia Therapeutics (AKBA)

Akebia Therapeutics Inc (AKBA) is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for patients with kidney disease. The company's primary product candidate, vadadustat, is an oral therapy that is being evaluated for the treatment of anemia associated with chronic kidney disease (CKD). CKD is a common and serious condition that affects millions of people worldwide, and anemia is a common complication of the disease. Currently, the standard of care for the treatment of anemia in CKD patients is injectable erythropoiesis-stimulating agents (ESAs), which have limitations and safety concerns. Vadadustat has the potential to be a new and improved treatment option for CKD patients with anemia.

Akebia Therapeutics Inc (AKBA) has experienced both positive and negative developments in recent years. In 2019, the company announced positive top-line results from its global Phase 3 program evaluating vadadustat for the treatment of anemia in CKD patients. The results showed that vadadustat met the primary and key secondary endpoints, demonstrating non-inferiority and superiority to ESAs in increasing hemoglobin levels. This was a significant milestone for the company and highlighted the potential of vadadustat as a new standard of care for anemia in CKD. However, in 2020, Akebia Therapeutics faced a setback when the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for vadadustat. The FDA requested additional data to further evaluate the cardiovascular safety of vadadustat before considering its approval. Akebia Therapeutics is currently working on addressing the FDA's concerns and resubmitting the NDA.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. John P. Butler MBA
Headquarters: Cambridge
Employees: 204
Exchange: NASDAQ

Keep an eye on Akebia Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Akebia Therapeutics 's (AKBA) price per share?

The current price per share for Akebia Therapeutics (AKBA) is $1.37. The stock has seen a price change of $0.02 recently, indicating a 1.48% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Akebia Therapeutics (AKBA)?

For Akebia Therapeutics (AKBA), the 52-week high is $2.48, which is 81.02% from the current price. The 52-week low is $0.78, the current price is 75.64% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Akebia Therapeutics (AKBA) a growth stock?

Akebia Therapeutics (AKBA) has shown an average price growth of 0.41% over the past three years. It has received a score of 80 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Akebia Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Akebia Therapeutics (AKBA) stock price performance year to date (YTD)?

As of the latest data, Akebia Therapeutics (AKBA) has a year-to-date price change of 7.87%. Over the past month, the stock has experienced a price change of -8.05%. Over the last three months, the change has been 45.74%. Over the past six months, the figure is -25.14%. Looking at a longer horizon, the five-year price change stands at -69.69%.

help

Is Akebia Therapeutics (AKBA) a profitable company?

Akebia Therapeutics (AKBA) has a net income of -$51.92M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 61.09% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -19.99% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $194.62M, although specific revenue growth data is currently not available. The gross profit is $118.89M. Operating income is noted at -$46.08M. Furthermore, the EBITDA is $4.08M.

help

What is the market capitalization of Akebia Therapeutics (AKBA)?

Akebia Therapeutics (AKBA) has a market capitalization of $283.89M. The average daily trading volume is 1.18M, indicating the stock's liquidity and investor engagement.